Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results
August 07, 2024 09:15 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Announces Publication of Phase 2 Results for Sapacitabine in Elderly AML Patients in the Lancet Oncology
November 01, 2012 07:00 ET
|
Cyclacel Pharmaceuticals, Inc.
Study Provides Support for SEAMLESS, an Ongoing, Phase 3, Registration-Directed Trial in Elderly Patients With Newly Diagnosed AML
Updated Survival Data From a Pilot Study and Lead-In Phase of...